查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529647

头颈癌治疗市场规模、份额、趋势分析报告：依治疗类型、给药途径、通路、地区、细分市场预测，2024-2030年

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

头颈癌治疗市场的成长与趋势：

Grand View Research 的最新报告显示，到 2030 年，全球头颈癌治疗市场规模预计将达到 44.3 亿美元。

预计2024年至2030年该市场将以11.8%的复合年增长率成长。头颈癌 (HNC) 诊断和治疗的不断进步预计将推动市场成长，因为它比手术更具成本效益且更有针对性。各类 HNC 盛行率的增加和老年人口的增加是市场的关键驱动因素。

据癌症研究所称，2021年美国约有54,000人被诊断出患有不同类型的HNC，约11,000人死亡。大量饮酒、长时间暴露在阳光下、致癌病毒感染（如EB病毒(EBV)）和烟草消费是导致全球各种头颈癌发生率增加的一些主要因素。

此外，根据联合国估计，到2020年，全球60岁以上人口将达到约7.27亿。此外，老年人口预计将从2020年的9.3%增加到2050年的16%。老龄化会降低免疫力并增加对各种类型 HNC 的易感性，从而增加了对该疾病治疗方法的需求。

此外，新型标靶药物和多模式治疗方法的研发活动的增加预计将提高头颈癌患者的存活率。例如，默克/Debiopharm的Xevinapant目前正处于治疗头颈部鳞状细胞癌的III期临床试验。它已被美国FDA指定为突破性疗法。

支持性报销政策预计也将推动市场成长。一些组织为患者及其看护者提供购买药品的经济援助。例如，2022 年 7 月，英国癌症协会将Capecitabine、卡铂、Carboplatin、Cetuximab、Cisplatin、阿霉素、Fluorouracil和亚叶酸钙列入其益处清单。此清单中包含的药物有资格因其核准的适应症而获得报销。

头颈癌治疗市场报告亮点

  • 免疫疗法引领市场，2023年占全球收益占有率的60.07%，预计在预测期内将以最快的复合年增长率成长。
  • 注射药物将在 2023 年引领市场，预计在预测期内复合年增长率为 12.0%。注射剂在全身性治疗中发挥重要作用，提供标靶药物来对抗恶性癌细胞。
  • 零售和专业药品在 2023 年以 57.67% 的市场占有率引领市场，预计在预测期内将以最快的 CAR 成长。
  • 由于头颈癌盛行率不断上升、人们对恶性治疗的认识不断提高、可支配收入增加以及医疗改革取得进展，亚太地区头颈癌治疗市场预计将成为市场中成长最快的市场。

目录

第一章调查方法与范围

第二章执行概述

第三章头颈癌治疗市场变数、趋势与范围

  • 头颈癌治疗市场的系统展望
    • 母市场展望
    • 辅助市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 头颈癌治疗市场分析工具
    • 波特五力分析
    • 宏观经济分析
  • 管道分析
    • 临床试验三期管线药物

第四章头颈癌治疗市场：依治疗类型的业务分析

  • 头颈癌治疗市场：治疗类型变异分析
  • 2023 年和 2030 年治疗类型变化分析和市场占有率
  • 化疗
  • 免疫疗法
  • 标靶治疗

第五章头颈癌治疗市场：给药途径的业务分析

  • 头颈癌治疗市场：给药途径变化分析
  • 2023年及2030年给药途径变化分析及市场占有率
  • 注射
  • 口服

第六章头颈癌治疗市场：通路的业务分析

  • 头颈癌治疗市场：通路波动分析
  • 2023年及2030年通路波动分析及市场占有率
  • 零售/专业药房
  • 医院药房
  • 网路药房

第七章头颈癌治疗市场：区域估计与趋势分析，依治疗类型、给药途径、通路

  • 头颈癌治疗市场：区域展望
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 供应商情况
    • 2023年主要企业市场占有率分析
    • Eli Lilly and Company
    • Sanofi
    • Merck &Co., Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company（BMS）
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
  • Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
  • Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
  • The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Therapy Type and Route of Administration Segment Snapshot
  • 2.3 Distribution Channel Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope

  • 3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increase in Prevalence of Head and Neck Cancers
      • 3.2.1.2 Rising Geriatric Population
      • 3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
      • 3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Paucity of Data Related to Safety and Efficacy
      • 3.2.2.2 High Cost of Treatment
  • 3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Macroeconomic Analysis
  • 3.4 Pipeline Analysis
    • 3.4.1 Phase 3 Pipeline drugs under clinical trails

Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
  • 4.3 Chemotherapy
    • 4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4 Immunotherapy
    • 4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5 Targeted Therapy
    • 4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
  • 5.3 Injectable
    • 5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4 Oral
    • 5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
  • 6.3 Retail & Specialty Pharmacies
    • 6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4 Hospital Pharmacies
    • 6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5 Online Pharmacies
    • 6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel

  • 7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
  • 7.2 North America
    • 7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.2.3 Target Disease: Cancer Incidence
      • 7.2.2.4 Market and Competitive Scenario
      • 7.2.2.5 Regulatory Framework
      • 7.2.2.6 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.3.3 Target Disease: Cancer Incidence
      • 7.2.3.4 Market and Competitive Scenario
      • 7.2.3.5 Regulatory Framework
      • 7.2.3.6 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.3 Target Disease Prevalence
      • 7.3.2.4 Market and Competitive Scenario
      • 7.3.2.5 Regulatory Framework
      • 7.3.2.6 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.3 Target Disease Prevalence
      • 7.3.3.4 Market and Competitive Scenario
      • 7.3.3.5 Regulatory Framework
      • 7.3.3.6 Reimbursement Scenario
    • 7.3.4 France
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.4.3 Target Disease Prevalence
      • 7.3.4.4 Market and Competitive Scenario
      • 7.3.4.5 Regulatory Framework
      • 7.3.4.6 Reimbursement Scenario
    • 7.3.5 Spain
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.5.3 Target Disease Prevalence
      • 7.3.5.4 Market and Competitive Scenario
      • 7.3.5.5 Regulatory Framework
      • 7.3.5.6 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.6.3 Target Disease Prevalence
      • 7.3.6.4 Market and Competitive Scenario
      • 7.3.6.5 Regulatory Framework
      • 7.3.6.6 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.3 Target Disease Prevalence
      • 7.3.7.4 Market and Competitive Scenario
      • 7.3.7.5 Regulatory Framework
      • 7.3.7.6 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Key Country Dynamics
      • 7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.8.3 Target Disease Prevalence
      • 7.3.8.4 Market and Competitive Scenario
      • 7.3.8.5 Regulatory Framework
      • 7.3.8.6 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Key Country Dynamics
      • 7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.9.3 Target Disease Prevalence
      • 7.3.9.4 Market and Competitive Scenario
      • 7.3.9.5 Regulatory Framework
      • 7.3.9.6 Reimbursement Scenario
    • 7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.2.3 Target Disease Prevalence
      • 7.4.2.4 Market and Competitive Scenario
      • 7.4.2.5 Regulatory Framework
      • 7.4.2.6 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.3.3 Target Disease Prevalence
      • 7.4.3.4 Market and Competitive Scenario
      • 7.4.3.5 Regulatory Framework
      • 7.4.3.6 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.3 Target Disease Prevalence
      • 7.4.4.4 Market and Competitive Scenario
      • 7.4.4.5 Regulatory Framework
      • 7.4.4.6 Reimbursement Scenario
    • 7.4.5 Australia
      • 7.4.5.1 Key Country Dynamics
      • 7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.5.3 Target Disease Prevalence
      • 7.4.5.4 Market and Competitive Scenario
      • 7.4.5.5 Regulatory Framework
      • 7.4.5.6 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Key Country Dynamics
      • 7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.6.3 Target Disease Prevalence
      • 7.4.6.4 Market and Competitive Scenario
      • 7.4.6.5 Regulatory Framework
      • 7.4.6.6 Reimbursement Scenario
    • 7.4.7 South Korea
      • 7.4.7.1 Key Country Dynamics
      • 7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.7.3 Target Disease Prevalence
      • 7.4.7.4 Market and Competitive Scenario
      • 7.4.7.5 Regulatory Framework
      • 7.4.7.6 Reimbursement Scenario
    • 7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.2.3 Target Disease Prevalence
      • 7.5.2.4 Competitive Scenario
      • 7.5.2.5 Regulatory Framework
      • 7.5.2.6 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.3.3 Target Disease: Cancer Incidence
      • 7.5.3.4 Market and Competitive Scenario
      • 7.5.3.5 Regulatory Framework
      • 7.5.3.6 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.4.3 Target Disease Prevalence
      • 7.5.4.4 Competitive Scenario
      • 7.5.4.5 Regulatory Framework
      • 7.5.4.6 Reimbursement Scenario
    • 7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6 Middle East and Africa
    • 7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 Key Country Dynamics
      • 7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.2.3 Target Disease Prevalence
      • 7.6.2.4 Competitive Scenario
      • 7.6.2.5 Regulatory Framework
      • 7.6.2.6 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Key Country Dynamics
      • 7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.6.3.3 Target Disease Prevalence
      • 7.6.3.4 Competitive Scenario
      • 7.6.3.5 Regulatory Framework
      • 7.6.3.6 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 Key Country Dynamics
      • 7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.4.3 Target Disease Prevalence
      • 7.6.4.4 Competitive Scenario
      • 7.6.4.5 Regulatory Framework
      • 7.6.4.6 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Key Country Dynamics
      • 7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.5.3 Target Disease Prevalence
      • 7.6.5.4 Competitive Scenario
      • 7.6.5.5 Regulatory Framework
      • 7.6.5.6 Reimbursement Scenario
    • 7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2 Company Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Eli Lilly and Company
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Sanofi
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.7. Cumberland Pharmaceuticals, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.8. Bristol-Myers Squibb Company (BMS)
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.9. AstraZeneca
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.10. Takeda Pharmaceutical Company Limited
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.11. Teva Pharmaceutical Industries Ltd.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.12. F. Hoffmann-La Roche Ltd
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 UK Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 UK Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Australia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Head And neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Therapy type and route of administration segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
  • Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
  • Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
  • Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
  • Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
  • Fig. 24 Global oral market, 2018 - 2030 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
  • Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
  • Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 40 Key country dynamics
  • Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Oropharynx cancer incidence, 2020 - 2030
  • Fig. 48 Germany insurance coverage
  • Fig. 49 Key country dynamics
  • Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Larynx cancer incidence, 2020 - 2030
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 64 Key country dynamics
  • Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Japan pharmaceutical registration
  • Fig. 72 Key country dynamics
  • Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
  • Fig. 75 Regulatory details: China
  • Fig. 76 Exclusivity formula
  • Fig. 77 Key country dynamics
  • Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 80 Registration details: India
  • Fig. 81 Key country dynamics
  • Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
  • Fig. 84 Drug pricing: Australia
  • Fig. 85 Contribution of PBS by disease
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
  • Fig. 89 Key country dynamics
  • Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
  • Fig. 92 Reimbursement scenario: South Korea
  • Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Larynx Cancer Incidence, 2020 to 2030
  • Fig. 98 Regulatory framework
  • Fig. 99 Reimbursement scenario
  • Fig. 100 Key country dynamics
  • Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Larynx cancer incidence, 2020 to 2030
  • Fig. 105 Argentina pharmaceuticals registration details
  • Fig. 106 Argentina pharmaceuticals reimbursement details
  • Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 112 Regulatory framework: South Africa
  • Fig. 113 Regulatory framework: South Africa drug registration fees
  • Fig. 114 Key country dynamics
  • Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
  • Fig. 117 Key country dynamics
  • Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 120 Key country dynamics
  • Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 123 Regulatory framework: Kuwait
  • Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Key company categorization
  • Fig. 126 Company market share analysis, 2023
  • Fig. 127 Strategic framework